Publication
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials
Reprint from Nature Reviews Drug Discovery
Feb 01, 2021
Download

Anti-PD1/PDL1 monoclonal antibodies are paving the way to a new era of cancer care, having achieved the most success of existing immuno-oncology (IO) agents in clinical development. With 10 approved anti-PD1/PDL1 mAbs in the global market, the focus is now shifting to combination therapies. This report examines the current trends in anti-PL/PDL1 mAbs clinical trials and global recruitment rates, as well as new combination strategies.

IQVIA and Cancer Research Institute collaborated on the analyses and report which was published by Nature Reviews Drug Discovery in November 2020. This is the third year for the report, which has been widely read and cited by industry.

Contact Us